for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Odonate Therapeutics Inc

ODT.OQ

Latest Trade

28.57USD

Change

1.09(+3.97%)

Volume

346,618

Today's Range

27.41

 - 

28.95

52 Week Range

11.68

 - 

43.61

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
27.48
Open
27.41
Volume
346,618
3M AVG Volume
2.81
Today's High
28.95
Today's Low
27.41
52 Week High
43.61
52 Week Low
11.68
Shares Out (MIL)
32.19
Market Cap (MIL)
884.51
Forward P/E
-6.22
Dividend (Yield %)
--

Next Event

Q3 2019 Odonate Therapeutics Inc Earnings Release

Latest Developments

More

Odonate Therapeutics Says Qtrly Loss Per Share of $1.15

Odonate Therapeutics Says Offering Of Common Shares Priced At $26/Share

Odonate Therapeutics Announces Public Offering Of Shares Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Odonate Therapeutics Inc

Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).

Industry

Biotechnology & Drugs

Contact Info

4747 Executive Dr Ste 510

+1.858.2003830

https://www.odonate.com/

Executive Leadership

Kevin C. Tang

Chairman of the Board, Chief Executive Officer

Jeff L. Vacirca

Vice Chairman of the Board

Michael S. Hearne

Chief Financial Officer

John G. Lemkey

Chief Operating Officer

Joseph P. O'Connell

Chief Medical Officer

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-2.310

2018

-3.640

2019(E)

-4.415
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.53
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-60.21
Return on Equity (TTM)
-55.35

Latest News

BRIEF-Odonate Therapeutics Q4 Loss Per Share $0.81

* ODONATE THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017

BRIEF-Odonate Holdings Llc Reports A 11.5 Pct Stake In Odonate Therapeutics As Of Dec 6

* Reports A 11.5 Pct Stake In Odonate Therapeutics Inc AS OF DEC 6 - SEC FILING Source text: (http://bit.ly/2AU3onq) Further company coverage:

BRIEF-Boxer Capital LLC Reports 10.0 Pct Stake In Odonate Therapeutics As Of Dec 6

* BOXER CAPITAL LLC REPORTS 10.0 PERCENT STAKE IN ODONATE THERAPEUTICS INC AS OF DECEMBER 6 - SEC FILING

BRIEF-Odonate Therapeutics Announces Pricing Of Initial Public Offering

* ODONATE THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up